Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Abdelhak, Ahmed; Hottenrott, Tilman; Morenas‐Rodríguez, Estrella; Suárez‐Calvet, Marc; K. Zettl, Uwe; Haass, Christian; G. Meuth, Sven; Rauer, Sebastian; Otto, Markus; Tumani, Hayrettin; Huss, André

doi:10.3389/fneur.2019.00280

Public

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Published in Frontiers in Neurology • Mar 26, 2019

Authors:

Ahmed Abdelhak

Tilman Hottenrott

Estrella Morenas‐Rodríguez

Abstract

Background: In progressive multiple sclerosis (MS), glial activation is thought to be a relevant mechanism of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the emerging treatment era of primary progressive MS (PPMS), more important than ever. Objectives: To ...

Subject

Expanded Disability Status Scale

Glial fibrillary acidic protein

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!